Skip to content

Study · Non-randomized trial · n = 21 · 1994

9 results

Short and long-term cardiovascular effects of growth hormone therapy in growth hormone deficient adults.

Thuesen L, Jørgensen JO, Müller JR, Kristensen BO, Skakkebaek NE, Vahl N, Christiansen JS

Clinical endocrinology1 Nov 1994Cited by 65 (Europe PMC)

PMID7828351 (opens in a new tab)DOI10.1111/j.1365-2265.1994.tb01827.x (opens in a new tab)PepBankPUB-07828351
Publisher pagePubMedAsk about this study
Jump to 9 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study9

9 results from studies that gave the peptide. 9 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In GH-deficient adults in a double-blind cross-over study, heart rate showed a further 10% increase after 4 months of GH (P < 0.01), beyond the higher rate seen on placebo than in controls.

    In plain wordsIn adults with GH deficiency, heart rate rose a further 10% after 4 months of GH, compared with the placebo period.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseHeart rate at 4 months
    Study

    n = 21

    Comparator
    4 months placebo (double-blind cross-over)
    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 4 monthsAs given in this study (human).

    Measurements

    Heart rate increase
    10%
    after 4 months

    Source sentences

    Summary
    After 4 months of GH treatment, heart rate showed a further increase (10%, P < 0.01) and seemed to remain elevated after 16 months of GH therapy.
    1 context sentence
    Summary · context
    Doppler echocardiography was performed in 21 GH deficient patients after 4 months placebo and 4 months GH therapy, in a double blind cross-over study.
  2. 02HumanNon-randomized trialEfficacy outcome

    In GH-deficient adults, systolic blood pressure did not change significantly after GH treatment.

    In plain wordsIn GH-deficient adults, systolic blood pressure did not change significantly after GH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeSystolic blood pressure
    Study

    n = 21

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · 4 monthsAs given in this study (human).

    Source sentences

    Summary
    Systolic and diastolic blood pressures were significantly lower in placebo treated patients than in controls, and did not change significantly after GH treatment.
    1 context sentence
    Summary · context
    Doppler echocardiography was performed in 21 GH deficient patients after 4 months placebo and 4 months GH therapy, in a double blind cross-over study.
  3. 03HumanNon-randomized trialEfficacy outcome

    In GH-deficient adults, diastolic blood pressure did not change significantly after GH treatment.

    In plain wordsIn GH-deficient adults, diastolic blood pressure did not change significantly after GH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeDiastolic blood pressure
    Study

    n = 21

    Outcome group
    Blood pressure · Cardiovascular
    Studied dose
    Dose not stated · 4 monthsAs given in this study (human).

    Source sentences

    Summary
    Systolic and diastolic blood pressures were significantly lower in placebo treated patients than in controls, and did not change significantly after GH treatment.
    1 context sentence
    Summary · context
    Doppler echocardiography was performed in 21 GH deficient patients after 4 months placebo and 4 months GH therapy, in a double blind cross-over study.
  4. 04HumanNon-randomized trialEfficacy outcome

    In GH-deficient adults, left ventricular diastolic diameter increased nonsignificantly after GH therapy (P > 0.05).

    In plain wordsIn GH-deficient adults, heart chamber diameter increased after GH therapy, but the change was not significant.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeLeft ventricular diastolic diameter at 4 months
    Study

    n = 21

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 4 monthsAs given in this study (human).

    Source sentences

    Summary
    The left ventricular diastolic diameter was reduced in patients as compared to controls, but increased after 4 months GH therapy (P > 0.05) and seemed to increase further during prolonged GH treatment.
    1 context sentence
    Summary · context
    Doppler echocardiography was performed in 21 GH deficient patients after 4 months placebo and 4 months GH therapy, in a double blind cross-over study.
  5. 05HumanNon-randomized trialEfficacy outcome

    In GH-deficient adults, cardiac index increased by 20% following GH therapy.

    In plain wordsIn GH-deficient adults, cardiac index increased by 20% following GH therapy.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseCardiac index after GH therapy
    Study

    n = 21

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 4 monthsAs given in this study (human).

    Measurements

    Cardiac index increase
    20%
    following GH therapy

    Source sentences

    Summary
    Cardiac index was at the same level in controls and in placebo-treated patients, but increased by 20% following GH therapy and remained elevated after 16 and 38 months (P < 0.05) of GH substitution.
    1 context sentence
    Summary · context
    Doppler echocardiography was performed in 21 GH deficient patients after 4 months placebo and 4 months GH therapy, in a double blind cross-over study.
  6. 06HumanNon-randomized trialEfficacy outcome

    In GH-deficient adults, heart rate seemed to remain elevated after 16 months of GH therapy.

    In plain wordsIn GH-deficient adults, heart rate seemed to remain elevated during longer GH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseHeart rate at 16 months
    Study

    n = 13

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 16 monthsAs given in this study (human).

    Source sentences

    Summary
    After 4 months of GH treatment, heart rate showed a further increase (10%, P < 0.01) and seemed to remain elevated after 16 months of GH therapy.
    2 context sentences
    Summary · context
    In an open design study, 13 patients were reinvestigated following 16 months and 9 patients following 38 months of GH therapy.
    Summary · context
    Doppler echocardiography was performed in 21 GH deficient patients after 4 months placebo and 4 months GH therapy, in a double blind cross-over study.
  7. 07HumanNon-randomized trialEfficacy outcome

    In GH-deficient adults, cardiac index remained elevated after 16 months of GH substitution (P < 0.05).

    In plain wordsIn GH-deficient adults, cardiac index remained elevated during longer GH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseCardiac index at 16 months
    Study

    n = 13

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 16 monthsAs given in this study (human).

    Source sentences

    Summary
    Cardiac index was at the same level in controls and in placebo-treated patients, but increased by 20% following GH therapy and remained elevated after 16 and 38 months (P < 0.05) of GH substitution.
    2 context sentences
    Summary · context
    In an open design study, 13 patients were reinvestigated following 16 months and 9 patients following 38 months of GH therapy.
    Summary · context
    Doppler echocardiography was performed in 21 GH deficient patients after 4 months placebo and 4 months GH therapy, in a double blind cross-over study.
  8. 08HumanNon-randomized trialEfficacy outcome

    In GH-deficient adults, cardiac index remained elevated after 38 months of GH substitution (P < 0.05).

    In plain wordsIn GH-deficient adults, cardiac index remained elevated during longer GH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseCardiac index at 38 months
    Study

    n = 9

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 38 monthsAs given in this study (human).

    Source sentences

    Summary
    Cardiac index was at the same level in controls and in placebo-treated patients, but increased by 20% following GH therapy and remained elevated after 16 and 38 months (P < 0.05) of GH substitution.
    2 context sentences
    Summary · context
    In an open design study, 13 patients were reinvestigated following 16 months and 9 patients following 38 months of GH therapy.
    Summary · context
    Doppler echocardiography was performed in 21 GH deficient patients after 4 months placebo and 4 months GH therapy, in a double blind cross-over study.
  9. 09HumanNon-randomized trialEfficacy outcome

    In GH-deficient adults, left ventricular diastolic diameter seemed to increase further during prolonged GH treatment.

    In plain wordsIn GH-deficient adults, heart chamber diameter seemed to increase further during longer GH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseLeft ventricular diastolic diameter during prolonged treatment
    Study

    n: not reported in source

    Outcome group
    Heart function · Cardiovascular
    Studied dose
    Dose not stated · 16 and 38 monthsAs given in this study (human).

    Source sentences

    Summary
    The left ventricular diastolic diameter was reduced in patients as compared to controls, but increased after 4 months GH therapy (P > 0.05) and seemed to increase further during prolonged GH treatment.
    2 context sentences
    Summary · context
    In an open design study, 13 patients were reinvestigated following 16 months and 9 patients following 38 months of GH therapy.
    Summary · context
    Doppler echocardiography was performed in 21 GH deficient patients after 4 months placebo and 4 months GH therapy, in a double blind cross-over study.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.